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This review describes the definition, incidence, clinical implications, and magnetic resonance imaging (MRI) findings of
pseudoprogression of brain tumors, in particular, but not limited to, high-grade glioma. Pseudoprogression is an impor-
tant clinical problem after brain tumor treatment, interfering not only with day-to-day patient care but also the execu-
tion and interpretation of clinical trials. Radiologically, pseudoprogression is defined as a new or enlarging area(s) of
contrast agent enhancement, in the absence of true tumor growth, which subsides or stabilizes without a change in
therapy. The clinical definitions of pseudoprogression have been quite variable, which may explain some of the differ-
ences in reported incidences, which range from 9–30%. Conventional structural MRI is insufficient for distinguishing
pseudoprogression from true progressive disease, and advanced imaging is needed to obtain higher levels of diagnos-
tic certainty. Perfusion MRI is the most widely used imaging technique to diagnose pseudoprogression and has high
reported diagnostic accuracy. Diagnostic performance of MR spectroscopy (MRS) appears to be somewhat higher, but
MRS is less suitable for the routine and universal application in brain tumor follow-up. The combination of MRS and
diffusion-weighted imaging and/or perfusion MRI seems to be particularly powerful, with diagnostic accuracy reaching
up to or even greater than 90%. While diagnostic performance can be high with appropriate implementation and inter-
pretation, even a combination of techniques, however, does not provide 100% accuracy. It should also be noted that
most studies to date are small, heterogeneous, and retrospective in nature. Future improvements in diagnostic accuracy
can be expected with harmonization of acquisition and postprocessing, quantitative MRI and computer-aided diagnostic
technology, and meticulous evaluation with clinical and pathological data.
Level of Evidence: 3
Technical Efficacy: Stage 2
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Despite maximum treatment, glioblastoma remainsalmost universally fatal with a median survival of 12–
14 months.1 Current best care consists of maximum safe
resection, followed by radiotherapy and chemotherapy. A
limited benefit has been gained through adoption of temo-
zolomide into standard treatment.2 In a proportion of
patients, the combination of chemotherapy and radiation
provokes increased contrast agent uptake and enlargement
of residual tumor, or the appearance of new lesions mimick-
ing tumor progression. This phenomenon, referred to as
pseudoprogression, has become a major challenge in glio-
blastoma follow-up, as only surgery or serial imaging is con-
clusive, which risks a treatment delay for patients with true
progressive disease (PD) and uncertainties for patients and
treating physicians. Iatrogenic imaging abnormalities are not
unique to glioblastoma, and may also occur with radiother-
apy in metastasis and lower-grade glioma. The diagnosis of
pseudoprogression is not easily made by a single imaging
technique, although several modalities and strategies have
shown moderately high accuracy, usually in single-center tri-
als. This review will focus on magnetic resonance imaging
(MRI) methods in clinical practice and research, discuss
technical considerations, and appraise the potential value of
computational aids for the distinction of recurrent/progres-
sive brain tumor and chemoradiation effects. It is acknowl-
edged that imaging techniques exist beyond MRI in the
form of radioactive tracer studies as potential markers of
tumor activity and metabolism.
View this article online at wileyonlinelibrary.com. DOI: 10.1002/jmri.26171
Received Feb 4, 2018, Accepted for publication Apr 7, 2018.
*Address reprint requests to: M.S., Department of Radiology and Nuclear Medicine (Hs-220), Erasmus MC, University Medical Centre Rotterdam, PO Box
2040, 3000 CA Rotterdam, the Netherlands. E-mail: marion.smits@erasmusmc.nl
From the 1Lysholm Neuroradiology Department, National Hospital for Neurology and Neurosurgery, London, UK; 2Department of Brain Rehabilitation and
Repair, UCL Institute of Neurology, London, UK; 3Imaging Department, University College London Hospital, London, UK; 4Department of Neurology, The
Brain Tumor Centre at Erasmus MC Cancer Institute, Rotterdam, The Netherlands; and 5Department of Radiology and Nuclear Medicine, Erasmus MC,
University Medical Centre Rotterdam, Rotterdam, The Netherlands
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution
in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
VC 2018 The Authors Journal of Magnetic Resonance Imaging published by Wiley Periodicals, Inc.
on behalf of International Society for Magnetic Resonance in Medicine 1
Definition, Incidence, and Clinical Aspects of
Pseudoprogression
The initial observations that led to the systematic evaluation
of pseudoprogression were made by clinicians who noticed
some patients clinically deteriorating during or shortly after
radiotherapy with increasing lesions on imaging, and with
subsequent improvement without intervening treatments.3
With an initially reported incidence of 10%, such cases
were considered relatively infrequent, but still mandated the
recommendation not to allow patients who relapsed within
3 months of radiotherapy into phase II studies, as this
might result in unreliable study outcomes. This 3-month
postradiotherapy exclusion period was clearly arbitrary.
Following the demonstration of improved outcome
when temozolomide was added to radiotherapy, several stud-
ies reexplored the occurrence of pseudoprogression and
treatment-related necrosis. These made the clinical landscape
of treatment-induced changes more complex. Chamberlain
et al4 reported more frequent radiation necrosis without evi-
dence of true PD in glioblastoma patients undergoing com-
bined chemoirradiation with temozolomide. This
observation was made in a series of 51 glioblastoma
patients, 26 of whom showed radiological progression
within the first 6 months of the completion of radiother-
apy.4 In 15 of these 26 patients (ie, 29% of all 51 patients),
histological evaluation showed only necrosis. Importantly, all
reoperated patients were referred for clinical and radiological
progression. This incidence, but also the timing of the
occurrence of necrosis, is different from historical series,
which already suggested an increased rate of radiation necro-
sis if radiotherapy was combined with chemotherapy.5,6
Shortly afterwards, two groups reported on early radio-
logical progression with spontaneous improvement without
further treatment. Taal et al8 described radiological progres-
sion at the first scan made 4 weeks after the end of
radiotherapy in 36 out of 85 patients. Of these, 18
improved or remained radiologically and clinically stable for
6 months and were diagnosed with pseudoprogression. Clin-
ical signs of deterioration were found in 6 of 18 patients
with pseudoprogression, versus 12 of 18 patients with early
progressive disease (ePD). Patients with pseudoprogression
were significantly younger than those with ePD. Pseudo-
progression was found to be unrelated to the size of the
radiotherapy field and was observed regardless of initial sur-
gical intervention (biopsy or resection). Brandes et al9
reported a similar study on 103 patients, and found early
radiological signs of progression in 50 of these patients. In
32 (ie, 31% of all 103 patients) the diagnosis of pseudo-
progression was made, while in 18 patients (17%) ePD was
found. Again, patients with pseudoprogression tended to be
less often clinically symptomatic than patients with ePD
(34% vs. 57%), and their tumors were more often O6-
methylguanine methyltransferase (MGMT) promotor meth-
ylated. These early data have since by and large been con-
firmed in other series.
What Is Pseudoprogression?
Radiologically, pseudoprogression is defined as a new or
enlarging area(s) of contrast agent enhancement occurring
early after the end of radiotherapy (eg, within 3–4 months),
in the absence of true tumor growth, which subsides or sta-
bilizes without a change in therapy7 (Fig. 1).
The clinical definitions of pseudoprogression have
been quite variable, which may explain some of the differ-
ences in reported incidences. Some series required lesions to
decrease (partial response) or remain stable for at least 6
months in order to diagnose pseudoprogression,3,8 while
others only used a 2-month interval after the first radiother-
apy scan to establish this diagnosis.9 In a recent article try-
ing to evaluate the role of pseudoprogression in a phase III
FIGURE 1: Serial contrast-enhanced (CE) T1-weighted (T1w) imaging showing increase 3 months and spontaneous decrease 6
months after combined radiotherapy and temozolomide of contrast-enhancement, edema, and mass effect.
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trial on bevacizumab in newly diagnosed glioblastoma and
using a systematic approach, clinical signs and symptoms
were taken as evidence of true PD, which is not supported
by the earlier studies on pseudoprogression.10 The study
also used the second MRI scan made as early as 8 weeks
later to decide whether true PD was present, and reported a
low incidence of pseudoprogression. However, other studies
found ongoing pseudoprogression at that point in time. An
important contribution of the latter study to this field was
the use of an immediate preradiotherapy scan as the baseline
for comparison with the postradiotherapy scan. Older series
generally used pre- or immediate postsurgery scans for eval-
uation, which allows surgical changes and tumor progression
prior to the start of radiotherapy to weigh in. Another issue
that limits the evaluation of pseudoprogression in the mod-
ern era is the rapid change to a new line of treatment in
radiologically progressing patients. If in that scenario a
tumor stabilizes or decreases in size, the underlying cause of
resolution of abnormalities cannot be established with any
certainty.
Incidence and Outcome
The recently reported incidence of pseudoprogression varies
widely, ranging from 9% to 30%.10–14 Importantly, it takes
patients with clinical deterioration and pseudoprogression
on average 7 months to recover.9 With the blurred distinc-
tion between pseudoprogression and frank radiation necro-
sis, it is clear that there is not a specific point in time when
a radiological increase equals tumor recurrence with 100%
certainty, but the uncertainty is most troublesome in the
first 3 months after the end of radiotherapy. It is not incon-
ceivable that many of the anecdotal long-term survivors in
trials on recurrent glioblastoma may reflect such cases.
Several studies suggest that patients with pseudoprog-
ression have better survival than the entire group of patients.
This type of analysis typically fails to correct for the survivor
bias, in that to be diagnosed with pseudoprogression one
has to already have survived for a certain period of
time.9,11,12 Some association with MGMT and isocitrate
dehydrogenase (IDH) status has been observed in several
series, with more frequent pseudoprogression in patients
with MGMT promotor methylated and IDH mutated
(which are typically also MGMT promotor methylated)
tumors. Not unlikely, this is related to the worse outcome
in patients with MGMT promotor unmethylated tumors,
suffering from earlier tumor progression than patients with
MGMT promotor methylation. However, pseudoprogres-
sion also occurs in MGMT promotor unmethylated cases.
Another series reported 18 cases of radiation necrosis in a
series of 159 patients undergoing second surgery for a glio-
blastoma, in which survival was not improved in patients
who suffered from radiation necrosis compared to patients
undergoing surgery for PD.15
Pseudoprogression Versus Radiation Necrosis
From these early studies, two different patterns emerge: one
group with treatment effects observed immediately at the
end of radiotherapy, and one group in which clinical and
radiological signs are observed at a later stage and who are
diagnosed with treatment-related necrosis at the time of sec-
ond surgery. The common denominator in all these patients
is that MRI suggested tumor progression, but outcome
proved otherwise. Systematic reports on surgical specimens
of cases operated for (early) pseudoprogression are rare. In
some early cases frank tumor is visible, making the diagnosis
straightforward, but frequently variable amounts of treat-
ment effects and tumor remnants are present.16 In these
clinical series, survival after surgery for pseudoprogression or
radiation necrosis is commonly not improved. The presence
of cases with mixed morphology consisting of both treat-
ment effects and tumor emphasize the limitations of biopsy
to clarify the nature of these clinically challenging cases of
early progression. At the histological and at the mechanistic
level, early pseudoprogression and radiation necrosis may
represent different pathophysiological processes, where some
patients with early pseudoprogression continue to develop
true radiation necrosis, while others may improve. Probably,
radiation therapy treatment induces damage to epithelial
cells and local tissue inflammation, which result in edema
and abnormal vessel permeability in which vascular endothe-
lial growth factor (VEGF) signaling is upregulated, which in
turn can cause an increase in edema seen on T2-weighted
images and/or new or increased contrast agent enhance-
ment.17 These processes are likely to be enhanced by effec-
tive systemic therapies. True radiation necrosis may reflect
more severe cases with more extensive tissue and vascular
damage, resulting in frank necrosis with fybrinoid necrosis,
hyalinization of vessel walls, and reactive gliosis, representing
a permanent tissue injury. Radiation necrosis emerges from
around 6 months to several years posttreatment. Studies
report the frequency of radiation necrosis between 5–
25%.5,18 Its incidence depends on cumulative dose and frac-
tionation, with an increased frequency after stereotactic
radiosurgery (SRS).19
Treatment for Pseudoprogression and
Radiation Necrosis
Awareness of the extent of the clinical problem but also of
the limitations of conventional imaging is a major part of
the clinical approach. Obtaining a proper baseline scan
acquired immediately prior to radiotherapy will prevent
some false assessments of (pseudo)progression. It is clear
that the immediate postradiotherapy scan should not be
used for routine decisions on treatment, but serves as a base-
line scan for further management. In clinically asymptom-
atic patients with radiological progression, treatment will
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continue as planned; if clinical deterioration occurs, steroids
and surgery will be considered. In challenging cases, surgery
can provide greater diagnostic certainty and reduce steroid
usage. Steroids are equally effective in controlling signs and
symptoms from pseudoprogression and radiation necrosis.
In the modern age, although not in all countries, that role
has partly been taken over by anti-VEGF agents, in particu-
lar bevacizumab.20 A small series on cediranib, a tyrosine
kinase inhibitor of VEGF, suggested a lower frequency of
pseudoprogression in cediranib-treated patients.21 Similarly,
the analysis of a large phase III study observed only 2%
pseudoprogression in bevacizumab-treated patients, versus
9% in the control arm.10
Other Instances of Pseudoprogression and
Treatment-Related Effects
Low-Grade Glioma
Treatment-related effects suggesting progression are not lim-
ited to glioblastoma. In a recent series, “pseudoprogression”
was documented in 13 of 63 (21%) of low-grade glioma
patients, occurring within a range of 3–78 months after
radiotherapy, with relatively small areas of contrast agent
enhancement compared to true PD.22
Metastatic Disease
Radiation necrosis is also a well-known phenomenon in
patients with brain metastasis treated with SRS. This may
occur after a median interval of 7 to 11 months, but some-
times after more than 5 years. Radiation necrosis may
explain up to half of the lesions that progress radiologically
after SRS.23,24
Immunotherapy
Pseudoprogression effects have been observed with use of
immunotherapy in cancer6,25 and concern exists that such
changes may also occur in glioblastoma patients treated with
immunotherapy (Fig. 2).26,27 Immunotherapies have shown
promising results in the treatment of cancer dissemination
to the brain (eg, melanoma), but there is yet limited data
on the incidence of pseudoprogression in immune-treated
glioblastoma. In the absence of truly effective immunothera-
pies for glioblastoma this remains largely a speculative prob-
lem. The frequency and timing of pseudoprogressive
changes has not been fully explored, but based on prelimi-
nary evidence most appear to occur within 6 months, con-
sisting of temporary deterioration of treated deposits with
subsequent regression or stabilization.27 It has been sug-
gested that the occurrence of pseudoprogression is associated
with an improved clinical prognosis.
Other Effects
Transient contrast agent enhancing abnormalities may mani-
fest in the first months after Gliadel wafer placement.28
An entity to be mentioned among probably delayed
radiation effects is the SMART (stroke-like migraine attacks
after radiotherapy) syndrome. This manifests as recurrent
neurological symptoms, including headaches and seizures,
associated with (usually unilateral) T2 hyperintense brain
signal abnormalities and gyriform cortical enhancement29
(Fig. 3). Its pathophysiological mechanism is incompletely
understood, but hyperexcitability and endothelial damage
are thought to be involved.
Response Criteria
The issue of pseudoprogression led to a change in response
evaluation criteria (the Response evaluation in NeuroOncol-
ogy [RANO] criteria) and to the recommendation not to
enroll patients relapsing within 3 months from the end of
radiotherapy in trials on recurrent glioblastoma, unless the
recurrence is histologically proven or the progressive abnor-
malities lie outside the radiation field.7 This comes at the
expense of a potential treatment delay for patients with early
glioblastoma recurrence within the radiotherapy bound-
aries.11 After that, RANO requires a >25% increase in the
FIGURE 2: Serial postcontrast T1-weighted imaging of a 34-year-old male patient with dural metastasis from melanoma, treated
with pembrolizumab. Treatment was continued despite initial increase of the lesion, which eventually responded. This patient also
exhibited extracranial immune response to the treatment. Images courtesy of Drs. M. Jasperse and H. van Thienen at the Nether-
lands Cancer Institute, Amsterdam (NL).
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product of the lesion bidirectional diameter to diagnose PD.
One study has questioned whether the RANO classification
of small volume (<25%) tumor growth as “stable” disease
could negatively impact outcomes.30 On the contrary, overdi-
agnosis of PD in patients with only minor glioblastoma
growth could result in unwarranted termination of effective
treatment. To optimize response assessment for
immunotherapy-treated patients, modified so-called iRANO
criteria have been devised (Fig. 4), which advocate serial
image assessment for enlarging or apparently nonresponding
lesions in the first 3–6 months to avoid misdiagnosis of tran-
sient phenomena.27
Current MRI Approaches to
Pseudoprogression
Conventional MRI
Glioblastoma proliferates rapidly, outgrows and newly indu-
ces vascularization to maintain oxygenation and nutrient
supply. Its newly formed tumor vessels are characterized by
endothelial abnormalities and increased permeability,31,32
which contributes to glioblastoma imaging hallmarks of
contrast agent enhancement, central necrosis, and hypervas-
cularity on perfusion studies33 (Fig. 5). Conventional struc-
tural MRI, performed before and after contrast agent
injection, does not allow a reliable distinction of
FIGURE 3: Postcontrast T1-weighted images of a 41-year-old male patient 3 years after radiotherapy for low-grade glioma. Com-
pared with (A) there is an increase in—predominantly cortical—enhancement (B). Note that there is also increased rCBV (C) and
no diffusion abnormalities (D). Follow-up imaging after 2 months (E) demonstrates spontaneous resolution of findings, consistent
with SMART syndrome.
FIGURE 4: iRANO diagnostic algorithm for progressive imaging findings in brain tumor immunotherapy recipients (adapted from
Ref. 30).
Thust et al.: Pseudoprogression of Brain Tumors
Month 2018 5
pseudoprogression and true PD,14 as both may share fea-
tures of mass effect, perilesional edema, and contrast agent
enhancement due to blood–brain barrier breakdown. Simi-
larly, for radiation necrosis and tumor, T1- and T2-weighted
(T2w) features overlap. Qualitative enhancement descriptors
of therapy-induced enhancement patterns (“soap bubble,
swiss cheese, moving wave front” (Fig. 6) are subjective and
have limited reproducibility.34 Nevertheless, perceived lesion
differences and enhancement morphology35 could poten-
tially become quantifiable in the era of image texture analy-
sis. It is important to note that contrast-enhanced T1w
image signal is also dependent on contrast dose, injection
timing, magnetic field strength, and choice of image
sequence.
At present, structural MRI remains the most univer-
sally available diagnostic method for monitoring treated
glioblastoma,36 both in clinical practice and as the basis for
trials. It fulfils a key role in serial comparison, and should
be performed according to standardized protocols to
maximize comparability.37 A recent meta-analysis found the
pooled incidence of pseudoprogression on conventional
MRI, defined as any transient worsening of lesions on T1w
and/or T2w images,
38 to be a frequent event: Abbasi et al
identified 73 studies in 2603 patients, of which 36% (95%
confidence interval [CI], 33–40%) demonstrated some form
of pseudoprogression. For those studies (nine studies,
n5 295) in which the use of RANO criteria was explicitly
stated, the pooled incidence was similar 37% (95%, CI 22–
52%).38 Conventional MRI detects T1w and T2w/FLAIR
lesion changes, but is not sufficient by itself for comprehen-
sive follow-up after brain tumor treatment.
Advanced MRI
Due to the diagnostic limitations of structural MRI,
advanced techniques are extensively investigated for their
ability to distinguish pseudoprogression and true PD, under
the assumption that imaging of pathophysiology will pro-
vide more accurate information than merely visualizing—
FIGURE 5: MRI features of histopathologically proven glioblastoma: Contrast-enhanced (CE) T1-weighted (T1w) sequences shows
an enhancing lesion in the left frontal lobe, with areas of central necrosis. There is increased rCBV (green/red) in the enhancing
tumor portions. Note there also hemorrhage in the left parieto-occipital region.
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unspecific—structural changes. A recent systematic review
and meta-analysis identified 45 studies on the diagnostic
accuracy of advanced and/or structural MRI in the assess-
ment of adult high-grade glioma response to first-line stan-
dard therapy according to the Stupp protocol.39 The final
findings from this meta-analysis were based on 35 studies
including a total of 1174 patients with a mean tumor preva-
lence of 60% (range 31–85%). This meta-analysis showed
the highest diagnostic accuracy for MR spectroscopy (nine
studies, 203 patients), followed by perfusion imaging
(dynamic susceptibility contrast [DSC] perfusion, 18 stud-
ies, 708 patients, and dynamic contrast enhanced [DCE]
perfusion, five studies, 207 patients). All advanced MRI
techniques had higher diagnostic accuracies than anatomical
imaging (five studies, 166 patients), for which the pooled
sensitivity was 68% (95% CI, 0.51–0.81) and pooled specif-
icity 77% (95% CI, 0.45–0.93) to distinguish between true
PD and treatment induced changes.
Perfusion MRI
Perfusion MRI forms a well-established component of gli-
oma follow-up. In a recent survey among 220 European
institutions, this technique was regarded as the modality of
choice to distinguish radiation effects from tumor progres-
sion by the vast majority of institutions.37
DSC constitutes the primarily used method for brain
tumor perfusion MRI. In two meta-analyses on advanced
and perfusion MRI for response assessment, DSC was the
most widely used perfusion technique (18/35 and 20/28
studies, respectively).39,40 DSC perfusion MRI relies on the
T2 and T2* shortening effects of gadolinium-based contrast
agents and involves rapid imaging to capture the signal
changes due to the first passage of an intravenously
administered contrast agent bolus (Table 1). The main
parameter derived from DSC MRI in the context of brain
tumors is the relative cerebral blood volume (rCBV). rCBV
is increased in high-grade tumor due to the presence of
increased microvascular density and many slow-flowing col-
lateral vessels. Many DSC studies have demonstrated that
maximum rCBV is lower in areas of radiation necrosis or
pseudoprogression compared to true PD, with reported
accuracies in individual studies for the distinction between
treatment effects and PD exceeding 90%33,41–45 (Fig. 7). In
two recent meta-analyses performed in the era of the Stupp
protocol, pooled sensitivities and specificities for the best-
performing parameters were also high: 87% (95% CI,
0.82–0.91) to 90% (95% CI, 0.85–0.94) sensitivity; and
86% (95% CI, 0.77–0.91) to 88% (95% CI, 0.83–0.92)
specificity.39,40 It should be noted that these analyses do not
differentiate between late radiation necrosis and the early
treatment effects of pseudoprogression. Patel et al assessed
the subset of 13 studies reporting on pseudoprogression,
although treatment was not always specified in these studies,
and found similar diagnostic accuracy, with pooled sensitiv-
ity and specificity of 89% (95% CI, 0.83–0.94) and 80%
(95% CI, 0.72–0.86) respectively.40
An important limitation of the technique is the fact
that it is only semiquantitative (hence the term relative
CBV), and that model assumptions are violated when there
is leakage of contrast agent from the intra- to the extravas-
cular compartment, which is invariably the case in enhanc-
ing tumor. This problem can be (partly) overcome by the
use of a preload bolus to saturate the tissues prior to DSC
acquisition and to additionally use leakage correction algo-
rithms46–49 (Fig. 8). Still, quantification and reproducibility
issues hamper the establishment of universal threshold values
FIGURE 6: Histopathologically confirmed pseudoprogression, where postcontrast T1-weighted images show a “swiss cheese” or
“soap bubble” increase of the margin of the lesion in the right frontal lobe.
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of rCBV for diagnosing pseudoprogression reliably. This is
illustrated by the wide range of reported thresholds, from
0.90–2.15 for mean rCBV ratios, and from 1.49–3.10 for
maximum rCBV ratios.40 Of note is that diagnostic accuracy
is higher when maximum rCBV is used, which can be
explained by intratumoral heterogeneity and the coexistence
of tumor and necrotic or inflammatory changes. For the lat-
ter reason, methodology has been proposed to quantify spa-
tial heterogeneity, with parameters such as rCBV histogram
skewness and kurtosis,50 or the tumor fractional vol-
ume.42,51 Using single-voxel rCBV ratio thresholding with a
cutoff of 1.0 in a study of 25 glioblastoma patients with
posttreatment changes, Hu et al were able to determine the
histological tumor fraction and to better predict overall sur-
vival than when mean rCBV was used.51 While these meth-
ods seem to capture global pathophysiological changes more
accurately, the requirement for segmentation of the abnor-
malities render these time- and labor-consuming, and thus
impractical in clinical routine.
An alternative, and less commonly employed technique
is DCE MRI, which involves T1-weighted imaging after
contrast agent injection over a prolonged period of time
(typically 5 minutes or longer) to assess the leakage of con-
trast agent through the blood–brain barrier (Table 1). The
volume transfer constant (Ktrans) is the most commonly
used parameter as a measure of vascular permeability, noting
that it is also representative of blood flow and vessel surface
area.52 It should be noted that quantification is highly
dependent on the pharmacokinetic models used. Ktrans tends
to be lower in areas of radiation necrosis,53 as well as in
pseudoprogression.54 Proposed Ktrans thresholds may
vary,55,56 with none widely established to date (Fig. 9).
DCE may also help in cases where DSC is uninterpretable
due to susceptibility artifacts, such as hemorrhage or surgical
clips, although in such cases DSC with a spin, rather than
gradient echo acquisition can also be considered. A com-
monly employed scenario is the acquisition of DCE during
the injection of the preload bolus that is given in prepara-
tion for DSC. Diagnostic accuracy of DCE is similar to
that of DSC, with pooled sensitivity of 89% (95% CI,
0.78–0.96) to 92% (95% CI, 0.73–0.98) and specificity of
85% (95% CI, 0.76–0.92).39,40 Due to the variability of
TABLE 1. Sample Protocol for Acquiring DCE and DSC Perfusion Imaging
Dynamic contrast enhanced
(DCE) perfusion136,137
Dynamic susceptibility
contrast (DSC) perfusion48
Pulse sequence T1w T2*w
Echo time (TE) 2 msec 25–35 msec at 3T; 40–45 msec at 1.5T
Repetition time (TR) 4–7 msec As fast as possible, preferably 1500 msec
Flip angle 15 degrees 60–70 degrees
Number of dynamics
(duration)
70 (5–15min) Baseline (prior to injection) minimum 10;
total 120 (1.5–2min)
Slice thickness 5mm 3–5mm
In-plane resolution 1–2mm2 2–3mm2
Contrast injection rate 2–3ml/s followed by saline flush 5ml/s followed by saline flush
Preload contrast bolus Not necessary; if DSC is also performed,
DCE can be acquired during the preload
contrast bolus administered for DSC.
Recommended, approximately
5–10min prior to acquisition
FIGURE 7: Postcontrast T1-weighted images and rCBV map (C) demonstrating glioblastoma resection cavity containing blood with
early postoperative rim enhancement (A), followed by pseudoprogression 2 months later (B,C) and spontaneous lesion resolution
(D,E) over the course of 3 further months.
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parameters used for quantification, no universal thresholds
can be established.
A “static” permeability assessment method, which
exploits delayed extravasation of contrast agent, has been
introduced in the form of treatment response assessment
maps (TRAMS). With this technique, a delayed (>1 hour)
postcontrast agent scan is performed to distinguish between
regions of contrast agent clearance (hypervascular tumor)
and contrast accumulation (nontumor tissues) (Fig. 10). In
a study of 150 patients with both primary and metastatic
brain tumors, 100% sensitivity and 92% positive predictive
value for identifying active tumor was reported.57 This find-
ing seems to be based on 51 tissue samples, 47 of which
included tumor tissue; it is unclear what findings were in
the remainder of the 99 patients, and in the absence of an
estimate of its specificity, diagnostic accuracy of this tech-
nique remains unclear.
A noninvasive perfusion MRI technique is arterial spin
labeling (ASL), which uses magnetically labeled blood as an
endogenous tracer58,59 (Fig. 11). Although its use is not
widespread for neuro-oncological indications, there are vari-
ous advantages of this versus the contrast-agent-based perfu-
sion imaging techniques, such as in patients with poor renal
function, difficult intravenous access (after chemotherapy),
and expected long-term follow-up with the risk of gadolin-
ium retention (pediatric population). Probably the biggest
advantage of ASL is that cerebral blood flow (CBF) quanti-
fication is not affected by leakage effects with blood–brain
barrier disruption, allowing for more accurate quantifica-
tion.60 Several studies have shown that DSC and ASL find-
ings correlate well and that accuracy for detecting,
classifying, and grading a variety of brain tumors is simi-
lar.61–64 Studies focusing on pseudoprogression/radiation
necrosis with ASL specifically are scarce. One study found
high correlation between ASL and DSC for differentiating
between PD and radiation necrosis.65 An earlier study
reported higher sensitivity of ASL (94%) than DSC perfu-
sion MRI (71%) to identify PD versus radiation necrosis;
specificity at this cutoff threshold ratio (1.3), however, was
very low with both techniques (50% and 40% with ASL
and DSC, respectively).66
MRS
The qualitative spectroscopy findings of tumor and therapy
effects differ. Recurrent brain neoplasms exhibit elevation of
choline (Cho) as a reflection of increased cell membrane
FIGURE 8: Postcontrast T1-weighted images of the same patient showing an enhancing lesion that remained stable over 1 year
follow-up. DSC imaging was acquired with a preload bolus and rCBV maps were calculated. Without leakage correction, rCBV
ratios are high; with leakage correction, rCBV ratios are low and more consistent with the clinically observed stable disease than
active tumor tissue.
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turnover.67 Features of radiation necrosis include a variable
decrease in n-acetyl-aspartate (NAA), lack of pronounced
Cho elevation, and the presence of lipid-lactate peaks68,69
(Fig. 12).
MRS strongly depends on technical parameters: Single
voxel spectroscopy measures the average of metabolite con-
centration within the chosen image volume, which is fraught
with inaccuracies and may prevent a clear distinction of PD
FIGURE 9: Postcontrast images (A), DSC-rCBV maps (B,C), T2w image (D) and DCE signal intensity curves (E) showing coexisting
radiation necrosis (region of interest 4, type 1 curve showing progressive enhancement) and tumor (arrow, type 3 curve showing
rapid washout) in a patient with anaplastic astrocytoma 2.5 years following radiotherapy. This was followed by spontaneous
enhancing lesion resolution (F,G).
FIGURE 10: Postcontrast T1-weighted images show an enhancing lesion (arrow) in the left temporal lobe of a patient treated for
recurrent glioblastoma. Images obtained 80 minutes postinjection show retention of the contrast agent, resulting in dark signal
on the subtraction image, suggestive of nontumoral tissue. One year follow-up shows spontaneous near complete lesion
resolution.
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from therapy effects. Multivoxel techniques (including
chemical shift imaging, CSI) more realistically depict mixed
lesions, and can help identify surgical targets. The choice of
echo time (TE) can have profound effects on the detection
of certain metabolites. For example, lipids are best visible
using short (35 msec) echo times, whereas an inverted
lactate peak (inconsistently) occurs at a longer echo (144
msec).70
Earlier results for the use of MRS in treated brain
tumors were positive, whereby several studies achieved a
good to excellent (80–97% accuracy) distinction between
tumor recurrence and radiation necrosis using Cho/NAA
FIGURE 11: Postcontrast T1-weighted image (A), DSC derived rCBV (B), and ASL derived CBF (C) maps showing no perfusion
abnormality in contrast enhancing radiation necrosis.
FIGURE 12: Postcontrast T1-weighted images, DSC perfusion rCBV maps and MRS of radiation necrosis (A–C, MRS with short
TE530 msec) versus glioblastoma (D–F, MRS with intermediate TE5144 msec).
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and Cho/Cr ratios.71–73 More recently, Kazda et al and
Bulik et al carried out two studies using CSI at one institu-
tion, which yielded >90% sensitivity and specificity for the
distinction of recurrent glioblastoma from pseudoprogres-
sion.68,74 This high diagnostic accuracy was confirmed in
one meta-analysis, with reported pooled sensitivity of 91%
(95% CI, 0.79–0.97) and specificity of 95% (95% CI,
0.65–0.99).39 In another meta-analysis, Zhang et al reported
somewhat lower pooled sensitivity and specificity of the
most commonly used Cho/NAA ratios (88% and 86%,
respectively) for differentiating recurrent glioma from radia-
tion necrosis, recommending MRS only in a multimodal
approach.75 Nevertheless, MRS has not found very wide-
spread clinical application for this indication. Proposed
numerical thresholds vary by as much as 50% of total
metabolite concentrations, and may strongly depend on
technique and the tumor type examined.74,76 Some of the
studies pursuing threshold cutoffs include mixed tumor
types or grades, for which metabolite ratios are known to
vary even prior to treatment.71 The use of ratios rather than
absolute metabolite concentrations potentially further limits
MRS comparability.
It has been hypothesized that MRS might confer dif-
ferent information to structural MRI by providing details
on lesion metabolism and viability. This is supported by the
discovery that metabolic tumor volumes only partially over-
lap with, or may exceed, macroscopic tumor bound-
aries.77–79 The question therefore arises as to how far
knowledge of metabolic tumor volumes could influence
treatment decisions, particularly if discrepant from structural
changes.78
Diffusion-Weighted Imaging
Water motion is reduced in rapidly growing tissues;
diffusion-weighted imaging (DWI) can therefore act as
potential biomarker of tumor cellularity.80 Consistent associ-
ations have been shown between glioma apparent diffusion
coefficient (ADC) and proliferative indices.81–83 For treated
glioblastomas, true PD has been found to exhibit generally
lower ADC values compared with pseudoprogression. Mini-
mum ADC, lower histogram percentiles, but also mean
ADC have been proposed as identifiers of pseudoprogres-
sion, with trends towards greater sensitivity than specific-
ity.84–86 ADC thresholds vary between studies and are
dependent on b values, with high (3000 s/mm2) b values
potentially being more accurate with a lesser signal-to-noise
ratio.87
Recent meta-analyses suggested moderate diagnostic
performance for diffusion-weighted MRI in differentiating
glioma recurrence from radiation necrosis (pooled sensitivity,
71–82%; pooled specificity, 84–87%).39,88 While somewhat
lower than MRS and perfusion MRI techniques, this
diagnostic performance is still superior to that of conven-
tional structural imaging.
ADC measurements, particularly using mean values,
have limited accuracy when applied to heterogeneous
tumors or to necrosing tissue, in which diffusivity may
evolve from cytotoxic edema to liquefaction89; furthermore,
interobserver variations in region of interest placement have
the potential to alter quantitative results.
The spatial pattern of ADC values is of diagnostic
interest,89,90 both for a single timepoint assessment and
follow-up. Serial voxel-wise mapping of diffusion could be
superior to identify subtle focal changes, but entirely
depends on accurate coregistration and requires additional
processing time.91,92 Parametric mapping is considered
unsuitable for patients with significant changes in mass
effect and brain shift between scans.
Diffusion tensor imaging (DTI) parameters, such as
high fractional anisotropy in recurrent glioblastoma, may
differentiate between tumor and therapy changes, but it
remains to be established whether these outperform three-
directional DWI.93 The results are contradictory regarding
the ability of DTI to predict glioma relapse sites.94,95 Multi-
band imaging is an emerging technique, which permits
rapid acquisition of advanced diffusion sequences using
multiple b values.96 This can be exploited to model tissue
microstructure in greater detail, eg, in the form of neurite
orientation and dispersion imaging (NODDI). Intravoxel
incoherent motion (IVIM) aims to simultaneously measure
diffusion and perfusion effects in tissue. Such techniques
have shown promising results for preoperative brain tumor
characterization, and could be of interest for the identifica-
tion of pseudoprogression.97
A multimodal approach, eg, using a combination of
diffusion and perfusion might add accuracy,98 but does not
consistently appear superior. It should be noted that for
antiangiogenic therapy (eg, bevacizumab) recipients, diffu-
sion assessment may be confounded, because low ADC can
be observed as a feature of coagulative necrosis but also in
glioblastoma recurrence.99
Novel Methods
Superparamagnetic Iron Oxides (SPIO)
SPIO nanoparticles have been identified as a promising
intravenous contrast alternative to gadolinium-based contrast
agents. Among these, ferumoxytol received FDA approval in
2009 as a drug to treat iron deficiency anemia. It has since
been researched (off label) for various brain imaging indica-
tions and has the advantage of no renal excretion. Because
nanoparticles are larger than gadolinium compounds, they
remain intravascular even where the blood–brain barrier is
disrupted; therefore, no leakage correction is required if
these are used for perfusion imaging.100 Ferumoxytol-
derived rCBV has been shown to correlate with treated
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glioblastoma survival.100 Quantitative rCBV results obtained
from ferumoxytol perfusion MRI appear comparable to or
slightly higher than those calculated from a standard dose
gadoteridol bolus in human brain.101 SPIO uptake may
assist the characterization of inflammatory processes via
localization of macrophage subtypes and as such could be
exploited to confirm the efficacy of immunotherapies.102
Since 2015, ferumoxytol carries an FDA warning, which
recommends slow (over 15 minutes) infusion in diluted
form to avoid anaphylaxis. A recent publication of 671 cases
receiving 3ml/sec bolus injections reported around 10%
adverse reactions (up to 15% for allergy sufferers) but with-
out any life-threatening events identified.103
Chemical Exchange Saturation Transfer (CEST)
CEST is an MRI contrast mechanism in development to
gain functional information about tumor metabolic pro-
cesses.104 The most widely trialed technique for brain tumor
imaging is endogenous CEST, aimed at identifying amide
proton transfer (APT) as a pH-dependent measure of pro-
tein turnover. With this method, a selective (“saturation”)
radiofrequency pulse is applied to exchangeable solute amide
protons, from which the saturation becomes transferred
onto surrounding water molecules (“water pool”) through
chemical exchange and/or dipolar interactions.105 With pro-
gressive saturation, the water signal amplitude of the meta-
bolically active tissue diminishes, which can be depicted as
an image. The origins of CEST contrast are complex and
incompletely understood, with magnetic cross-relaxation
effects (nuclear Overhauser enhancement, NOE) apparently
contributing to APT signal in brain tumors.106,107 Endoge-
nous CEST appears to identify viable aggressive tumor, hav-
ing shown greater signal towards higher grades and most
recently in IDH wildtype gliomas,108,109 and for this reason
could be of interest for follow-up of treated brain tumors.
In preclinical research, Zhou et al recently distinguished gli-
oma and radiation necrosis and were able to demonstrate a
serial glioma APT signal reduction subsequent to treat-
ment.110 More recently, two human studies achieved a sta-
tistically significant separation of glioblastoma from
pseudoprogression (Ma et al, n5 32), and of metastases
from radiation necrosis (Mehrabian et al, n5 16) at 3T
using amide and NOE contrasts, respectively.111,112
Texture Analysis and Machine Learning
“Texture” refers to the spatial arrangement of signal intensi-
ties in an image. Texture analysis is a summary term for
computational methods that assess and quantify imaging
features beyond what can be observed by the human eye.
First-order statistics are the simplest method, consisting of
an extraction of image signal intensities from a histo-
gram.113 From this, parameters such as mean and standard
deviation as well as curve shape (skewness, kurtosis) can be
calculated. Second-order statistics assess the relationship
between two image pixels; third- and higher-order statistics
evaluate three or more pixel relationships to identify more
complex image patterns. This can be applied as computer-
learning methods, which operate by progressively eliminat-
ing nonspecific traits (“classifiers”) from a learning sample
until the most unique traits are selected. The learned knowl-
edge is subsequently tested in an independent sample for
validation, a method that has already shown potential for
brain tumor differential diagnosis and glioma subtyp-
ing.114,115 First-order features of ADC and rCBV appear
useful for identifying therapy changes in glioblastoma.50,85
Chaddad and Tanougast successfully used a second-
order method (gray-level co-occurrence matrix, GLCM) to
correlate glioblastoma morphology such as the extent of
necrosis with survival.114 GLCM was also trialed for T1-
weighted, T2-weighted, and T2-fluid-attenuated inversion
recovery (FLAIR) MRI, achieving an accuracy of 86% for
the differentiation of glioblastoma from pseudoprogres-
sion.116 Booth et al distinguished pseudoprogression from
true PD with >85% accuracy using descriptors of image
heterogeneity called Minkowski functionals, further
highlighting the potential value of anatomical MRI texture
analysis.117 Learning methods can be adapted to permit
more or less liberal classifications, depending on whether
sensitivity or specificity is most desirable.118
With regard to advanced modalities, Hu et al inte-
grated automated segmentations of anatomical sequences,
ADC and DSC derived metrics (rCBV, rCBF) into a sup-
port vector machine (SVM) learning model with excellent
results (AUC, 0.94).118 SVM may be useful for distinction
of metastases and radiation necrosis.119 In SVM testing,
Cho was suggested as the most discriminatory MRS parame-
ter in early treated glioblastoma but with relatively low
(<70%) accuracy.120
Discussion
Pseudoprogression is an important clinical problem after
brain tumor treatment, interfering not only with day-to-day
patient care but also the execution and interpretation of
clinical trials. Conventional anatomical MRI is insufficient
for distinguishing pseudoprogression from true PD; how-
ever, it represents the diagnostic basis for serial lesion meas-
urements. It is recommended to incorporate RANO
bidirectional axial measurements into reporting37 and, where
possible, to consider transitioning to volumetric tumor
assessment.121 But the questions of incidence and timing of
pseudoprogression are incompletely resolved,11,38 due to
heterogeneity in the radiological and clinical definitions and
only scarce histopathological data. As such, the RANO stan-
dard is imperfect but widely practicable and can mitigate at
least some of the uncertainty.
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Advanced MRI allows a higher level of diagnostic cer-
tainty, but so far no (combination of) imaging technique(s)
has 100% accuracy. Despite the high levels of diagnostic
accuracy reported in many advanced MRI studies, it should
be noted that these studies are generally small, heteroge-
neous, and retrospective in nature.
Furthermore, there are varying definitions of pseudo-
progression, both in imaging and clinical studies, hampering
the interpretation and pooling of published studies. For
many of the advanced MRI studies, the gold standard to
distinguish pseudoprogression from PD consists of a mix-
ture of serial imaging and biopsy,68,73 which has inherent
inaccuracies. Imaging and clinical follow-up are most com-
monly used, while histological diagnosis is generally consid-
ered the gold standard. Even for those studies where biopsy
is performed for histological diagnosis, these may suffer
from sampling bias and may incompletely capture mixed
lesions. Melguizo-Gavilanes et al also demonstrated the
complexity of interpreting surgical samples and highlighted
that current criteria for histological confirmation may in
fact not be such a robust standard to distinguish pseudo-
progression from true PD.16
Some advanced MRI techniques are well established in
clinical practice, whereas others predominate in research.
Potential hurdles to clinical translation can arise from lack
of hardware or software, time pressure, or not being trained
in using the modality.37 Countless technical parameters can
influence acquisition quality and postprocessing48; further-
more, thresholds proposed in the advanced imaging litera-
ture are mostly unvalidated, which further contributes to
uncertainty. To define sufficiently sensitive and specific val-
ues is especially problematic for techniques with small per-
centage differences in signal for the disease entities to be
distinguished. Advanced MRI techniques are not currently
incorporated into RANO or other response criteria, but
efforts are ongoing to standardize techniques and develop
quantitative MRI biomarkers (eg, QIBA/RSNA http://qiba-
wiki.rsna.org/index.php/Perfusion,_Diffusion_and_Flow-
MRI_Biomarker_Ctte).
Perfusion MRI is the most widely used imaging tech-
nique to diagnose pseudoprogression and has high reported
diagnostic accuracy. Diagnostic performance of MRS
appears to be somewhat higher, but due to its lengthy acqui-
sition time, low spatial resolution, technical challenges, and
quality issues such as near surgical clips, MRS is less suitable
for the routine and universal application in brain tumor
follow-up. Overall, MRS appears highly valuable as an
adjunct for identifying therapy effects: it may confer differ-
ent information and be complementary to structural MRI.
The combination of MRS and DWI and/or perfusion imag-
ing seems to be particularly powerful, with diagnostic accu-
racy reaching 90%,122,123 and even >90% when all three
techniques are used.124 Again, however, it is important to
note that these studies are relatively small, heterogeneous,
and limited in number. It also needs to be pointed out that
there are other imaging modalities for diagnosing pseudo-
progression that are not addressed here. This concerns in
particular positron emission tomography (PET) with amino
acid tracers. Recent studies reported similar diagnostic accu-
racy to advanced MRI of fluoro-ethyl-tyrosine (FET) PET
of at least 85% for differentiating both typical (within 12
weeks) and late (>12 weeks) pseudoprogression after radio-
chemotherapy completion from true PD.125
DSC and DCE perfusion MRI seem to be more or
less equivalent in terms of diagnostic performance, with
DSC being faster and much more widely used. One poten-
tial, but as yet rarely exploited advantage of DCE, is its
higher spatial resolution compared with DSC, allowing a
more accurate assessment of mixed lesions consisting of
both pseudoprogression and true PD. ASL is proposed as a
noninvasive alternative to DSC or DCE, which until
recently was considered hardly relevant, as postcontrast
imaging is integral to brain tumor follow-up. The recent
concerns regarding gadolinium retention and toxicity may
require a reevaluation of this routine, especially in young
patients and long-term survivors. Physiological imaging with
noninvasive techniques, such as ASL and CEST, may gain
in importance when these techniques further mature (faster
scanning, increased signal-to-noise ratio, higher spatial
resolution).
One consideration is whether to include advanced
techniques routinely in the brain tumor follow-up imaging
protocol. This will depend highly on the logistics and set-
up of the institution, particularly the ability to re-call the
patient for additional imaging if needed. It can be argued
that conventional imaging may suffice, if there is stable dis-
ease or partial/complete response. However, even in such
cases it may be beneficial to use advanced MRI to identify
early signs of malignant transformation.126 The advantages
of routine acquisition of advanced MRI for brain tumor
follow-up are the availability of its diagnostic information
when needed, a consistency of imaging protocols, and sus-
taining the experience by the radiographers and radiologists.
DSC perfusion MRI is well suited to be performed rou-
tinely, as it only takes about 2–3 minutes to acquire, and
the contrast agent dose can—especially at 3.0T—be kept
low, by splitting a single dose into preload and bolus
injection.
The greatest drawback of advanced MRI techniques is
the lack of standardization. Variations in equipment, acqui-
sition factors, and postprocessing methods are probably
impossible to avoid, but these continue to hamper the com-
parability between institutions, with great risk of distorting
even conventional serial imaging interpretation.127 For
image analysis methods requiring spatial registration, eg,
parametric mapping and subtraction techniques,57
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calculations heavily rely on technical accuracy. This problem
affects research trials, for which consensus recommendations
have recently been published to promote protocol standardi-
zation.128 With respect to clinical practice, the extent of the
effects of method variability is partially unknown, but
almost certainly represents a significant factor. As an exam-
ple, enhancing lesion visibility may be influenced by the
injection dose and speed, scan delay, choice of echo time,
slice thickness, and patient positioning, all of which may
negatively impact measurement accuracy and particularly
longitudinal, across-center assessment.129–131
Variations in acquisition and postprocessing methodol-
ogy furthermore preclude the universal implementation of
cutoff values into clinical practice.40 Some recommendations
on advanced MRI acquisition do exist, such as for DWI,132
ASL,133 and DSC,48 but are as yet lacking for postprocess-
ing and interpretation. Currently available advanced MRI
techniques are generally semiquantitative at best and results
may be profoundly altered by mathematical models, such
that absolute values cannot be used.48,134 This is commonly
dealt with by normalization to reference values, such as
from the contralateral normal-appearing white matter, but
there is no consensus on size or positioning of the reference
region. Worryingly, such postprocessing details are not con-
sistently reported in diagnostic studies of advanced MRI,
rendering their proposed threshold values essentially
meaningless.
Notwithstanding these numerous limitations, the avail-
able evidence, especially from several meta-analyses, strongly
supports the use of advanced MRI techniques for brain
tumor follow-up in the context of posttreatment changes.
Proposed threshold values in the literature, however, should
be applied with great care and are maybe only useful as gen-
eral guides. Ideally, a particular parameter or threshold value
is optimized and validated locally, and all postprocessing
methodology is applied consistently within the institution.
Ongoing efforts to standardize MRI acquisition and post-
processing may eventually allow for the identification of
robust thresholds to be implemented universally. Such
efforts are also essential for the development and implemen-
tation of computer-aided diagnostic techniques, which show
promise in distinguishing pseudoprogression from true PD,
but require large data throughput and consistent clinical
and pathological evaluation. For the moment, however,
much of the implementation of computer-aided diagnostic
or advanced image analysis techniques is also hampered by
the need for tumor segmentation, which generally requires
some form of user-input and which can be time-consuming.
Automated segmentation as part of the image processing
pipeline would resolve this issue. Additionally, it has been
suggested that when using automated segmentation, a cor-
rection of errors is possibly superior compared to assisting
the algorithm in areas of uncertainty, which could be more
efficient for clinical practice.135
Conclusion
Advanced MRI, particularly perfusion imaging and/or MRS,
needs to be applied for the follow-up of treated brain tumor
patients to distinguish pseudoprogression from true PD.
While diagnostic performance can be high with appropriate
implementation and interpretation, even a combination of
techniques does not provide 100% accuracy. Improvements
can be expected with harmonization of acquisition and post-
processing, quantitative MRI and computer-aided diagnostic
technology, and meticulous evaluation with clinical and
pathological data.
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